Suchergebnisse - "Papazafiropoulou, Athanasia"

PubPharm (113)

1

Sodium-Glucose Co-transporter 2 Inhibitors Versus Metformin as the First-Line Treatment for Type 2 Diabetes : Is It Time for a Revolution?

enthalten in: Cardiovascular drugs and therapy | 2023

von Koufakis, T. | Papazafiropoulou, A. | Makrilakis, K. | +1

2

Effects of Chios mastic gum on cardiometabolic risk factors

enthalten in: World journal of diabetes | 2022

von Papazafiropoulou, A.

3

Investigating Diabetes Mellittus Impact on Various Aspects of Patients' Quality of Life

enthalten in: Studies in health technology and informatics | 2022

von Kontoteza, I. | Dragamestianou, A. | Galanis, P. | +6

4

Investigating Diabetes Mellitus Patients' Experiences with Self Monitoring Blood Glucose Methods

enthalten in: Studies in health technology and informatics | 2022

von Dragamestianou, A. | Kontoteza, I. | Siskou, O. | +6

5

Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment

enthalten in: World journal of diabetes | 2022

von Florentin, M. | Kostapanos, M. | Papazafiropoulou, A.

6

Telemedicine and diabetes during the COVID-19 era

enthalten in: Archives of medical sciences. Atherosclerotic diseases | 2022

von Papazafiropoulou, A.

7

Sodium-Glucose Co-transporter 2 Inhibitors Versus Metformin as the First-Line Treatment for Type 2 Diabetes: Is It Time for a Revolution?

enthalten in: Cardiovascular drugs and therapy | 2021

von Koufakis, T. | Papazafiropoulou, A. | Makrilakis, K. | +1

8

Effect of 3-month therapy with empagliflozin on ambulatory blood pressure and arterial stiffness in patients with type 2 diabetes mellitus

enthalten in: Annals of African medicine | 2021

von Papazafiropoulou, A. | Mpoumi, L. | Papantoniou, S. | +3

9

Glycemic Control of Patients with Type 1 Diabetes Using an Insulin Pump Before and During the COVID-19-Associated Quarantine

enthalten in: Diabetes technology & therapeutics | 2021

von Barmpagianni, A. | Lambadiari, V. | Papazafiropoulou, A. | +4

10

Effects of Glucagon-like Peptide-1 Receptor Agonists and Sodium-glucose Cotransporter 2 Inhibitors on Cardiorenal and Metabolic Outcomes in People Without Diabetes

enthalten in: Current pharmaceutical design | 2021

von Papazafiropoulou, A. | Melidonis, A. | Antonopoulos, S.

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[12]